- Policy
- RSA refund should be differentiated by income
- by Kim, Jung-Ju Aug 27, 2021 05:59am
- Currently, it has been suggested that Korea should apply RSA's refund flexibly by differentiating it according to income. It is suggested that the government should reduce the refund of high-income earners according to the income distribution and strengthen the guarantee of high-weakness by operating the refund of low-income earners in the form
- Policy
- Clinical trials of Jardiance have been approved
- by Lee, Tak-Sun Aug 26, 2021 05:58am
- The SGLT-2 diabetes treatment has expanded its indication to other treatments for diseases such as heart failure. In Korea, AstraZeneca's Forxiga (Dapagliflozin Propanediol Hydrate) has also been recognized for its efficacy and effect on chronic heart failure and chronic kidney disease. And Boehringer Ingelheim's "Jardiance (Empagliflozin)" i
- Policy
- Ppl willing to pay max ₩13.52 mil. for one-shot therap
- by Kim, Jung-Ju Aug 26, 2021 05:58am
- Over 75% of the public responded that high-priced innovative new drugs, or so-called ‘one-shot treatments,’ should be covered by the National Health Insurance. As to the maximum price the public was willing to pay for such treatments, the average price was &8361;13.52 million, and the most amount of respondents - 33.3% - agreed to the price.
- Policy
- Drugs caught in rebates for 2 years can be replaced by fines
- by Kim, Jung-Ju Aug 26, 2021 05:58am
- Among the insurance drugs caught as rebates, drugs that have been claimed for two consecutive years based on the date of disposal are expected to be replaced by fines. It belongs to cases that may cause inconvenience in patient care, not to harm public welfare. In the case of fines on these drugs, the rate will be increased by varying the upp
- Policy
- Will the voluntary recovery of AZBT be expanded?
- by Lee, Tak-Sun Aug 25, 2021 05:57am
- More and more drugs are voluntarily recovered due to the excessive detection of impurities AZBT(Azido Methyl Bipheny Ttetrazole). On the 6th, the recovery of items produced before 2021 among three items containing Irvesartan (Rovelito, CoAprovel, and Arovel) was decided, and AZBT was also detected in a Valsartan compound produced by a domesti
- Policy
- Opdivo's benefit extends for kidney cancer & parietal cancer
- by Lee, Hye-Kyung Aug 25, 2021 05:57am
- As domestic No. 1 immuno-cancer drug "Opdivo (Nivolumb)" renewed its contract with RSA, the benefit standard has also been expanded. The HIRA will issue a "proposal to revise the announcement of drugs prescribed and dispensed to cancer patients" and will inquire about their opinions by the 25th. If there is no disagreement, the benefit will b
- Policy
- Janssen’s acetaminophen tablets may replace Tylenol
- by Lee, Tak-Sun Aug 24, 2021 06:06am
- Janssen Korea, which locally manufactures and sells Tylenol in Korea, has received import authorization for its product. The company is presumed to be making the move to secure alternatives in advance before stopping the operation of its Hyangnam plan at the end of this year. On the 23rd, the Ministry of Food and Drug safety approved Jan
- Policy
- The effectiveness of NIP expansion policy?
- by Aug 24, 2021 06:05am
- Moon Jae-in president announced to expand under the age of 17 for vaccine against cervical cancer vaccination for free, while the few people seemed to be criticizing as 'show off'. President Moon said he would expand the vaccination target from the age of 12 to the age of 17 to mark the 4th anniversary of the petition. In the past, peo
- Policy
- Over 40mil COVID-19 vaccines cleared for release in 6 mos
- by Lee, Tak-Sun Aug 23, 2021 05:55am
- The number of COVID-19 vaccines granted National Lot Release in Korea has exceeded 40 million. The large-scale batches of Pfizer vaccines introduced in late July have accelerated the number of vaccines approved for lot release. According to the Ministry of Food and Drug Safety on the 22nd, 1.6 million doses (for 800 thousand people) Pfize
- Policy
- Perjeta's price was down 10% to ₩2,214,600
- by Kim, Jung-Ju Aug 23, 2021 05:55am
- Five drugs that succeeded in insurance benefits in Korea due to Risk Sharing Agreement (RSA) have been re-contracted by lowering drug prices to the expiration of the contract. According to the industry, the MOHW is recently pushing to revise the list of drug benefits aimed at the 1st of next month for a total of five successful drugs negotia
